{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:10:07Z","timestamp":1789038607754,"version":"build-2803163510"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Mol Morphol"],"DOI":"10.1007\/s00795-026-00474-2","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:29:00Z","timestamp":1789036140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The mechanism of malignant progression in extramammary Paget\u2019s disease (EMPD): hallmarks of EMPD"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3080-1621","authenticated-orcid":false,"given":"Ikko","family":"Kajihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"474_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA (2023) The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41:374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016","journal-title":"Cancer Cell"},{"key":"474_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"key":"474_CR3","doi-asserted-by":"publisher","first-page":"e795","DOI":"10.1111\/1346-8138.17855","volume":"52","author":"S Matsushita","year":"2025","unstructured":"Matsushita S, Kajihara I, Tsutsui K, Hirai I, Maekawa T et al (2025) Japanese dermatological association guidelines: clinical questions of guidelines for extramammary Paget disease 2025. J Dermatol 52:e795\u2013e814. https:\/\/doi.org\/10.1111\/1346-8138.17855","journal-title":"J Dermatol"},{"key":"474_CR4","doi-asserted-by":"publisher","first-page":"10983","DOI":"10.1073\/pnas.211430998","volume":"98","author":"JR Testa","year":"2001","unstructured":"Testa JR, Bellacosa A (2001) AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98:10983\u201310985. https:\/\/doi.org\/10.1073\/pnas.211430998","journal-title":"Proc Natl Acad Sci USA"},{"key":"474_CR5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1172\/JCI119309","volume":"99","author":"VS Sivaraman","year":"1997","unstructured":"Sivaraman VS, Wang H, Nuovo GJ, Malbon CC (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99:1478\u20131483. https:\/\/doi.org\/10.1172\/JCI119309","journal-title":"J Clin Invest"},{"key":"474_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0304-419X(94)90012-4","volume":"1198","author":"NE Hynes","year":"1994","unstructured":"Hynes NE, Stern DF (1994) The biology of erbB-2\/neu\/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165\u2013184. https:\/\/doi.org\/10.1016\/0304-419X(94)90012-4","journal-title":"Biochim Biophys Acta"},{"key":"474_CR7","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3390\/diagnostics10121040","volume":"10","author":"G Angelico","year":"2020","unstructured":"Angelico G, Santoro A, Inzani F, Straccia P, Arciuolo D et al (2020) Hormonal environment and HER2 status in extra-mammary Paget\u2019s disease (eMPD): a systematic literature review and meta-analysis with clinical considerations. Diagnostics (Basel) 10:1040. https:\/\/doi.org\/10.3390\/diagnostics10121040","journal-title":"Diagnostics (Basel)"},{"key":"474_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/modpathol.3800243","volume":"18","author":"O Reich","year":"2005","unstructured":"Reich O, Liegl B, Tamussino K, Regauer S (2005) p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget\u2019s disease. Mod Pathol 18:354\u2013357. https:\/\/doi.org\/10.1038\/modpathol.3800243","journal-title":"Mod Pathol"},{"key":"474_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1600-0560.2008.01148.x","volume":"36","author":"JA Plaza","year":"2009","unstructured":"Plaza JA, Torres-Cabala C, Ivan D, Prieto VG (2009) HER-2\/neu expression in extramammary Paget disease: a clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy. J Cutan Pathol 36:729\u2013733. https:\/\/doi.org\/10.1111\/j.1600-0560.2008.01148.x","journal-title":"J Cutan Pathol"},{"key":"474_CR10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/jcp.2010.077446","volume":"63","author":"CE Richter","year":"2010","unstructured":"Richter CE, Hui P, Buza N, Silasi DA, Azodi M et al (2010) HER-2\/NEU overexpression in vulvar Paget disease: the Yale experience. J Clin Pathol 63:544\u2013547. https:\/\/doi.org\/10.1136\/jcp.2010.077446","journal-title":"J Clin Pathol"},{"issue":"3","key":"474_CR11","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ygyno.2007.12.014","volume":"111","author":"A Karam","year":"2008","unstructured":"Karam A, Berek JS, Stenson A, Rao J, Dorigo O (2008) HER-2\/neu targeting for recurrent vulvar Paget\u2019s disease A case report and literature review. Gynecol Oncol 111(3):568\u2013571. https:\/\/doi.org\/10.1016\/j.ygyno.2007.12.014","journal-title":"Gynecol Oncol"},{"key":"474_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/1346-8138.15096","volume":"47","author":"T Kimura","year":"2020","unstructured":"Kimura T, Akamatsu Y, Kajihara I, Fukushima S, Ihn H (2020) Case of metastatic extramammary Paget\u2019s disease treated with trastuzumab-biosimilar monotherapy after S-1 and docetaxel combination chemotherapy. J Dermatol 47:e1\u2013e2. https:\/\/doi.org\/10.1111\/1346-8138.15096","journal-title":"J Dermatol"},{"issue":"11","key":"474_CR13","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/1346-8138.15515","volume":"47","author":"N Sekiguchi","year":"2020","unstructured":"Sekiguchi N, Kubota S, Noguchi T, Fukushima T, Kobayashi T et al (2020) Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget\u2019s disease: four cases and a review. J Dermatol 47(11):1276\u20131279. https:\/\/doi.org\/10.1111\/1346-8138.15515","journal-title":"J Dermatol"},{"key":"474_CR14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-4702","author":"V Makker","year":"2026","unstructured":"Makker V, Lee JY, Oh DY, Oaknin A, Puvvada S et al (2026) Post-hoc analysis of the phase II DESTINY-PanTumor02 Study: local and central HER2 IHC concordance and trastuzumab Deruxtecan efficacy by HER2 IHC status in HER2-expressing solid tumors. Clin Cancer Res Epub. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-4702","journal-title":"Clin Cancer Res Epub"},{"key":"474_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000093854","volume":"213","author":"M Iijima","year":"2006","unstructured":"Iijima M, Uhara H, Ide Y, Sakai S, Onuma H et al (2006) Estrogen-receptor-\u03b1-positive extramammary Paget\u2019s disease treated with hormonal therapy. Dermatology 213:144\u2013146. https:\/\/doi.org\/10.1159\/000093854","journal-title":"Dermatology"},{"key":"474_CR16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1365-2133.2005.06865.x","volume":"153","author":"K Yoneyama","year":"2005","unstructured":"Yoneyama K, Kamada N, Kinoshita K, Kawashima T, Otani M et al (2005) Androgen-deprivation regimen for multiple bone metastases of extramammary Paget disease. Br J Dermatol 153:853\u2013855. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06865.x","journal-title":"Br J Dermatol"},{"key":"474_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69:16\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2764","journal-title":"Cancer Res"},{"key":"474_CR18","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028\u20131038. https:\/\/doi.org\/10.1056\/NEJMoa1315815","journal-title":"N Engl J Med"},{"key":"474_CR19","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1111\/jdv.18229","volume":"36","author":"S Yamada-Kanazawa","year":"2022","unstructured":"Yamada-Kanazawa S, Mijiddorj MT, Kajihara I, Kanemaru H, Sawamura S et al (2022) Upregulated androgen receptor variant-7 mRNA and protein in extramammary Paget\u2019s disease. J Eur Acad Dermatol Venereol 36:e724\u2013e726. https:\/\/doi.org\/10.1111\/jdv.18229","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"474_CR20","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-14-0816","volume":"21","author":"T VanArsdale","year":"2015","unstructured":"VanArsdale T, Boshoff C, Arndt KT, Abraham RT (2015) Molecular pathways: targeting the cyclin D-CDK4\/6 axis for cancer treatment. Clin Cancer Res 21:2905\u20132910. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0816","journal-title":"Clin Cancer Res"},{"key":"474_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14:130\u2013146. https:\/\/doi.org\/10.1038\/nrd4504","journal-title":"Nat Rev Drug Discov"},{"key":"474_CR22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/1346-8138.14858","volume":"46","author":"K Urata","year":"2019","unstructured":"Urata K, Kajihara I, Myangat TM, Tasaki Y, Otsuka-Maeda S et al (2019) Overexpression of cyclin-dependent kinase 4 protein in extramammary Paget\u2019s disease. J Dermatol 46:444\u2013448. https:\/\/doi.org\/10.1111\/1346-8138.14858","journal-title":"J Dermatol"},{"key":"474_CR23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/cas.15234","volume":"113","author":"S Kitamura","year":"2022","unstructured":"Kitamura S, Yanagi T, Maeda T, Ujiie H (2022) Cyclin-dependent kinase 4\/6 inhibitors suppress tumor growth in extramammary Paget\u2019s disease. Cancer Sci 113:802\u2013807. https:\/\/doi.org\/10.1111\/cas.15234","journal-title":"Cancer Sci"},{"key":"474_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.semcancer.2019.10.002","volume":"60","author":"Y Verhoeven","year":"2020","unstructured":"Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D et al (2020) The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol 60:41\u201356. https:\/\/doi.org\/10.1016\/j.semcancer.2019.10.002","journal-title":"Semin Cancer Biol"},{"key":"474_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1023\/a:1023805715476","volume":"22","author":"A Verma","year":"2003","unstructured":"Verma A, Kambhampati S, Parmar S, Platanias LC (2003) Jak family of kinases in cancer. Cancer Metastasis Rev 22:423\u2013434. https:\/\/doi.org\/10.1023\/a:1023805715476","journal-title":"Cancer Metastasis Rev"},{"key":"474_CR26","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/jjco\/hyab062","volume":"51","author":"S Otsuka-Maeda","year":"2021","unstructured":"Otsuka-Maeda S, Mijiddorj MT, Kajihara I, Sakamoto R, Yamada-Kanazawa S et al (2021) Overexpression of Janus kinase 2 protein in extramammary Paget\u2019s disease. Jpn J Clin Oncol 51:1176\u20131178. https:\/\/doi.org\/10.1093\/jjco\/hyab062","journal-title":"Jpn J Clin Oncol"},{"key":"474_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1476-4598-9-253","volume":"9","author":"R Cubas","year":"2010","unstructured":"Cubas R, Zhang S, Li M, Chen C, Yao Q (2010) Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 9:253. https:\/\/doi.org\/10.1186\/1476-4598-9-253","journal-title":"Mol Cancer"},{"key":"474_CR28","doi-asserted-by":"publisher","first-page":"7706","DOI":"10.3390\/ijms22147706","volume":"22","author":"T Ito","year":"2021","unstructured":"Ito T, Tanegashima K, Tanaka Y, Hashimoto H, Murata M et al (2021) Trop2 expression in extramammary Paget\u2019s disease and normal skin. Int J Mol Sci 22:7706. https:\/\/doi.org\/10.3390\/ijms22147706","journal-title":"Int J Mol Sci"},{"key":"474_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41598-024-84566-y","volume":"15","author":"T Ito","year":"2025","unstructured":"Ito T, Tanaka Y, Ogata D, Nishida H, Shiomi T et al (2025) A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan. Sci Rep 15:409. https:\/\/doi.org\/10.1038\/s41598-024-84566-y","journal-title":"Sci Rep"},{"key":"474_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biocel.2017.06.007","volume":"89","author":"S Siddharth","year":"2017","unstructured":"Siddharth S, Goutam K, Das S, Nayak A, Nayak D et al (2017) Nectin-4 is a breast cancer stem cell marker that induces WNT\/\u03b2-catenin signaling via Pi3k\/Akt axis. Int J Biochem Cell Biol 89:85\u201394. https:\/\/doi.org\/10.1016\/j.biocel.2017.06.007","journal-title":"Int J Biochem Cell Biol"},{"key":"474_CR31","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s11864-022-00940-w","volume":"23","author":"H Hashimoto","year":"2022","unstructured":"Hashimoto H, Tanaka Y, Murata M, Ito T (2022) Nectin-4: a novel therapeutic target for skin cancers. Curr Treat Options Oncol 23:578\u2013593. https:\/\/doi.org\/10.1007\/s11864-022-00940-w","journal-title":"Curr Treat Options Oncol"},{"key":"474_CR32","doi-asserted-by":"publisher","first-page":"e15049","DOI":"10.1111\/exd.15049","volume":"33","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Ito T, Murata M, Tanegashima K, Kaku-Ito Yet at. (2024) NECTIN4-targeted antibody-drug conjugate is a potential therapeutic option for extramammary Paget disease. Exp Dermatol 33:e15049","journal-title":"Exp Dermatol"},{"issue":"7","key":"474_CR33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/exd.15049","volume":"11","author":"M Taipale","year":"2010","unstructured":"Taipale M, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11(7):515\u2013528. https:\/\/doi.org\/10.1111\/exd.15049","journal-title":"Nat Rev Mol Cell Biol"},{"key":"474_CR34","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/1346-8138.16825","volume":"50","author":"T Ohnuma","year":"2023","unstructured":"Ohnuma T, Mijiddorj MT, Kajihara I, Sawamura S, Sakamoto R et al (2023) Overexpression of heat shock protein 90 through the downregulation of miR-9-5p in extramammary Paget\u2019s disease. J Dermatol 50:1216\u20131221. https:\/\/doi.org\/10.1111\/1346-8138.16825","journal-title":"J Dermatol"},{"key":"474_CR35","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1365-2230.2008.02851.x","volume":"33","author":"S Chen","year":"2008","unstructured":"Chen S, Moroi Y, Urabe K, Takeuchi S, Kido M et al (2008) Differential expression of two new members of the p53 family, p63 and p73, in extramammary Paget\u2019s disease. Clin Exp Dermatol 33:634\u2013640. https:\/\/doi.org\/10.1111\/j.1365-2230.2008.02851.x","journal-title":"Clin Exp Dermatol"},{"key":"474_CR36","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/bjc.1997.482","volume":"76","author":"M Takata","year":"1997","unstructured":"Takata M, Hatta N, Takehara K (1997) Tumour cells of extramammary Paget\u2019s disease do not show either p53 mutation or allelic loss at several selected loci implicated in other cancers. Br J Cancer 76:904\u2013908. https:\/\/doi.org\/10.1038\/bjc.1997.482","journal-title":"Br J Cancer"},{"key":"474_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","volume":"16","author":"H Garg","year":"2016","unstructured":"Garg H, Suri P, Gupta JC, Talwar GP, Dubey S (2016) Survivin: a unique target for tumor therapy. Cancer Cell Int 16:49. https:\/\/doi.org\/10.1186\/s12935-016-0326-1","journal-title":"Cancer Cell Int"},{"key":"474_CR38","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/j.1600-0560.2009.01437.x","volume":"37","author":"SJ Shan","year":"2010","unstructured":"Shan SJ, Zhang N, Geng SL, Zhou Z, Chen X et al (2010) Expression of survivin and human telomerase reverse transcriptase in extramammary Paget\u2019s disease. J Cutan Pathol 37:635\u2013640. https:\/\/doi.org\/10.1111\/j.1600-0560.2009.01437.x","journal-title":"J Cutan Pathol"},{"key":"474_CR39","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1038\/s41388-020-01405-w","volume":"39","author":"AN Guterres","year":"2020","unstructured":"Guterres AN, Villanueva J (2020) Targeting telomerase for cancer therapy. Oncogene 39:5811\u20135824. https:\/\/doi.org\/10.1038\/s41388-020-01405-w","journal-title":"Oncogene"},{"key":"474_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12935-019-1091-8","volume":"20","author":"K Li","year":"2020","unstructured":"Li K, Luo H, Huang L, Luo H, Zhu X (2020) Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 20:16. https:\/\/doi.org\/10.1186\/s12935-019-1091-8","journal-title":"Cancer Cell Int"},{"key":"474_CR41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10147-019-01498-8","volume":"25","author":"S Mishima","year":"2020","unstructured":"Mishima S, Taniguchi H, Akagi K, Baba E, Fujiwara Y et al (2020) Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. Int J Clin Oncol 25:217\u2013239. https:\/\/doi.org\/10.1007\/s10147-019-01498-8","journal-title":"Int J Clin Oncol"},{"key":"474_CR42","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/cas.14798","volume":"112","author":"K Akagi","year":"2021","unstructured":"Akagi K, Oki E, Taniguchi H, Nakatani K, Aoki D (2021) Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 112:1105\u20131113. https:\/\/doi.org\/10.1111\/cas.14798","journal-title":"Cancer Sci"},{"key":"474_CR43","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1002\/ski2.37","volume":"1","author":"K Kashiwada-Nakamura","year":"2021","unstructured":"Kashiwada-Nakamura K, Myangat TM, Kajihara I, Kusaba Y, Tanaka K et al (2021) Absence of microsatellite instability in extramammary Paget\u2019s disease. Skin Health Dis 1:e37. https:\/\/doi.org\/10.1002\/ski2.37","journal-title":"Skin Health Dis"},{"key":"474_CR44","doi-asserted-by":"publisher","unstructured":"Kang Z, Xu F, Zhang QA, Lin J, Wu Z et al (2012) Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget\u2019s disease. 25:1160\u20131168. https:\/\/doi.org\/10.1038\/modpathol.2012.65","DOI":"10.1038\/modpathol.2012.65"},{"key":"474_CR45","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/jdv.15404","volume":"33","author":"Z Kang","year":"2019","unstructured":"Kang Z, Zhu Y, Zhang QA, Dong L, Xu F et al (2019) Methylation and expression analysis of mismatch repair genes in extramammary Paget\u2019s disease. J Eur Acad Dermatol Venereol 33:874\u2013879. https:\/\/doi.org\/10.1111\/jdv.15404","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"474_CR46","doi-asserted-by":"publisher","first-page":"e13497","DOI":"10.1111\/srt.13497","volume":"29","author":"Z Kang","year":"2023","unstructured":"Kang Z, Jiang L, Chen D, Yan G, Zhang G et al (2023) Whole genome methylation sequencing reveals epigenetic landscape and abnormal expression of FABP5 in extramammary Paget\u2019s disease. Skin Res Technol 29:e13497. https:\/\/doi.org\/10.1111\/srt.13497","journal-title":"Skin Res Technol"},{"key":"474_CR47","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","volume":"14","author":"AM Schram","year":"2017","unstructured":"Schram AM, Chang MT, Jonsson P, Drilon A (2017) Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol 14:735\u2013748. https:\/\/doi.org\/10.1038\/nrclinonc.2017.127","journal-title":"Nat Rev Clin Oncol"},{"key":"474_CR48","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jid.2018.08.030","volume":"139","author":"G Zhang","year":"2019","unstructured":"Zhang G, Zhou S, Zhong W, Hong L, Wang Y et al (2019) Whole-exome sequencing reveals frequent mutations in chromatin remodeling genes in mammary and extramammary Paget\u2019s diseases. J Invest Dermatol 139:789\u2013795. https:\/\/doi.org\/10.1016\/j.jid.2018.08.030","journal-title":"J Invest Dermatol"},{"key":"474_CR49","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jdermsci.2019.03.006","volume":"94","author":"Y Kiniwa","year":"2019","unstructured":"Kiniwa Y, Yasuda J, Saito S, Saito R, Motoike IN et al (2019) Identification of genetic alterations in extramammary Paget disease using whole exome analysis. J Dermatol Sci 94:229\u2013235. https:\/\/doi.org\/10.1016\/j.jdermsci.2019.03.006","journal-title":"J Dermatol Sci"},{"key":"474_CR50","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/cam4.2820","volume":"9","author":"Z Gatalica","year":"2020","unstructured":"Gatalica Z, Vranic S, Kruslin B, Poorman K, Stafford P et al (2020) Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget\u2019s disease. Cancer Med 9:1441\u20131450. https:\/\/doi.org\/10.1002\/cam4.2820","journal-title":"Cancer Med"},{"key":"474_CR51","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1200\/PO.20.00073","volume":"4","author":"M Stasenko","year":"2020","unstructured":"Stasenko M, Jayakumaran G, Cowan R, Broach V, Chi DS et al (2020) Genomic alterations as potential therapeutic targets in extramammary Paget\u2019s disease of the vulva. JCO Precis Oncol 4:1054\u20131060. https:\/\/doi.org\/10.1200\/PO.20.00073","journal-title":"JCO Precis Oncol"},{"key":"474_CR52","doi-asserted-by":"publisher","unstructured":"Takeichi T, Okuno Y, Matsumoto T, Tsunoda N, Suzuki K et al. Frequent FOXA1-activating mutations in extramammary Paget\u2019s disease. Cancers 12:820. https:\/\/doi.org\/10.3390\/cancers12040820","DOI":"10.3390\/cancers12040820"},{"key":"474_CR53","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1158\/1078-0432.CCR-20-3205","volume":"27","author":"Y Ishida","year":"2021","unstructured":"Ishida Y, Kakiuchi N, Yoshida K, Inoue Y, Irie H et al (2021) Unbiased detection of driver mutations in extramammary Paget disease. Clin Cancer Res 27:1756\u20131765. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3205","journal-title":"Clin Cancer Res"},{"key":"474_CR54","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/bjd\/ljae337","volume":"192","author":"O Iwasawa","year":"2024","unstructured":"Iwasawa O, Ikegami M, Miyagawa T, Morita H, Saito H et al (2024) Association of genetic alterations with prognosis in extramammary Paget disease: insights into the involvement of somatic CDKN2A variants in patients with a poor prognosis. Br J Dermatol 192:46\u201354. https:\/\/doi.org\/10.1093\/bjd\/ljae337","journal-title":"Br J Dermatol"},{"key":"474_CR55","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrc.2016.35","volume":"16","author":"TH Carr","year":"2016","unstructured":"Carr TH, McEwen R, Dougherty B, Johnson JH, Dry JR et al (2016) Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer 16:319\u2013329. https:\/\/doi.org\/10.1038\/nrc.2016.35","journal-title":"Nat Rev Cancer"},{"key":"474_CR56","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1111\/1346-8138.16439","volume":"49","author":"Y Kusaba","year":"2022","unstructured":"Kusaba Y, Kajihara I, Myangat TM, Tanaka K, Kanemaru H et al (2022) Clinical significance of ERBB2 S310F mutation in extramammary Paget\u2019s disease. J Dermatol 49:e305\u2013e306. https:\/\/doi.org\/10.1111\/1346-8138.16439","journal-title":"J Dermatol"},{"key":"474_CR57","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.1038\/s41388-020-01404-x","volume":"39","author":"T Maeda","year":"2020","unstructured":"Maeda T, Kitamura S, Nishihara H, Yanagi T (2020) Extramammary Paget\u2019s disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies. Oncogene 39:5867\u20135875. https:\/\/doi.org\/10.1038\/s41388-020-01404-x","journal-title":"Oncogene"},{"key":"474_CR58","doi-asserted-by":"publisher","first-page":"6289","DOI":"10.2147\/OTT.S244814","volume":"13","author":"JJ Guo","year":"2020","unstructured":"Guo JJ, Jiao XD, Wu Y, Qin BD, Liu K et al (2020) Response to pyrotinib in a Chinese patient with bone-metastatic scrotal Paget\u2019s disease harboring triple uncommon HER2 mutation: a case report. Onco Targets Ther 13:6289\u20136293. https:\/\/doi.org\/10.2147\/OTT.S244814","journal-title":"Onco Targets Ther"},{"key":"474_CR59","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A et al (2020) Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov 10:1808\u20131825. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0522","journal-title":"Cancer Discov"},{"key":"474_CR60","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1158\/1078-0432.CCR-20-3205","volume":"27","author":"Y Ishida","year":"2020","unstructured":"Ishida Y, Kakiuchi N, Yoshida K, Inoue Y, Irie H et al (2020) Unbiased detection of driver mutations in extramammary Paget disease. Clin Cancer Res 27:1756\u20131765. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3205","journal-title":"Clin Cancer Res"},{"key":"474_CR61","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jaad.2023.11.057","volume":"90","author":"O Iwasawa","year":"2024","unstructured":"Iwasawa O, Miyagawa T, Omatsu J, Matsuda KM, Awaji K et al (2024) Mutational landscape of advanced extramammary Paget disease with comprehensive genomic profiling tests: a cohort study in a Japanese real-world setting. J Am Acad Dermatol 90:842\u2013845. https:\/\/doi.org\/10.1016\/j.jaad.2023.11.057","journal-title":"J Am Acad Dermatol"},{"key":"474_CR62","doi-asserted-by":"publisher","first-page":"e396","DOI":"10.1111\/1346-8138.16898","volume":"50","author":"Y Nakayama","year":"2023","unstructured":"Nakayama Y, Ogata D, Wada S, Tsuruta S, Matsui Y et al (2023) Treatment of high tumor mutation burden metastatic extramammary Paget disease with an anti-PD-1 antibody. J Dermatol 50:e396\u2013e397. https:\/\/doi.org\/10.1111\/1346-8138.16898","journal-title":"J Dermatol"},{"issue":"12","key":"474_CR63","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/nrc1753","volume":"5","author":"AG Bader","year":"2005","unstructured":"Bader AG, Kang S, Zhao L, Vogt PK (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5(12):921\u2013929","journal-title":"Nat Rev Cancer"},{"key":"474_CR64","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/1346-8138.16343","volume":"49","author":"Y Kusaba","year":"2022","unstructured":"Kusaba Y, Kajihara I, Myangat TM, Tanaka K, Sakamoto R et al (2022) Intertumor and intratumor heterogeneity of PIK3CA mutations in extramammary Paget\u2019s disease. J Dermatol 49:508\u2013514. https:\/\/doi.org\/10.1111\/1346-8138.16343","journal-title":"J Dermatol"},{"key":"474_CR65","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15:81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166","journal-title":"Nat Rev Clin Oncol"},{"key":"474_CR66","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168:613\u2013628. https:\/\/doi.org\/10.1016\/j.cell.2017.01.018","journal-title":"Cell"},{"key":"474_CR67","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1684\/ejd.2024.4609","volume":"34","author":"K Tanaka","year":"2024","unstructured":"Tanaka K, Kajihara I, Shimokawa K, Nakamura N, Kusaba Y et al (2024) Genetic intratumour heterogeneity and clonal evolution in extramammary Paget\u2019s disease. Eur J Dermatol 34:182\u2013192. https:\/\/doi.org\/10.1684\/ejd.2024.4609","journal-title":"Eur J Dermatol"},{"key":"474_CR68","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029\u20131033. https:\/\/doi.org\/10.1126\/science.1160809","journal-title":"Science"},{"key":"474_CR69","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1158\/0008-5472.CAN-11-1457","volume":"71","author":"F Hirschhaeuser","year":"2011","unstructured":"Hirschhaeuser F, Sattler UG, Mueller-Klieser W (2011) Lactate: a metabolic key player in cancer. Cancer Res 71:6921\u20136925. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1457","journal-title":"Cancer Res"},{"key":"474_CR70","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/jdv.16145","volume":"34","author":"K Urata","year":"2020","unstructured":"Urata K, Kajihara I, Miyauchi H, Mijiddorj T, Otsuka-Maeda S et al (2020) The Warburg effect and tumour immune microenvironment in extramammary Paget\u2019s disease: overexpression of lactate dehydrogenase A correlates with immune resistance. J Eur Acad Dermatol Venereol 34:1715\u20131721. https:\/\/doi.org\/10.1111\/jdv.16145","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"474_CR71","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-12-0977","volume":"18","author":"DM Miller","year":"2012","unstructured":"Miller DM, Thomas SD, Islam A, Muench D, Sedoris K (2012) c-Myc and cancer metabolism. Clin Cancer Res 18:5546\u20135553. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0977","journal-title":"Clin Cancer Res"},{"key":"474_CR72","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1097\/MNM.0000000000000340","volume":"36","author":"Y Tian","year":"2015","unstructured":"Tian Y, Wu H-B, Li D-L, Li H-S, Zhou W-L et al (2015) Utility of 18F-FDG PET\/CT in the diagnosis and staging of extramammary Paget\u2019s disease. Nucl Med Commun 36:892\u2013897. https:\/\/doi.org\/10.1097\/MNM.0000000000000340","journal-title":"Nucl Med Commun"},{"key":"474_CR73","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/1346-8138.13833","volume":"44","author":"M Fujiwara","year":"2017","unstructured":"Fujiwara M, Suzuki T, Senoo A, Fukamizu H, Tokura Y (2017) Evaluation of positron emission tomography imaging to detect lymph node metastases in patients with extramammary Paget\u2019s disease. J Dermatol 44:939\u2013943. https:\/\/doi.org\/10.1111\/1346-8138.13833","journal-title":"J Dermatol"},{"key":"474_CR74","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1111\/1346-8138.16328","volume":"49","author":"Y Kusaba","year":"2022","unstructured":"Kusaba Y, Kajihara I, Sawamura S, Kanemaru H, Makino K et al (2022) Clinical significance of maximum standardized uptake value of positron emission tomography\/computed tomography as prognostic factor in extramammary Paget\u2019s disease. J Dermatol 49:e201\u2013e202. https:\/\/doi.org\/10.1111\/1346-8138.16328","journal-title":"J Dermatol"},{"key":"474_CR75","doi-asserted-by":"publisher","unstructured":"Liu H, Urabe K, Uchi H, Takeuchi S, Nakahara T, Dainichi T, Tu Y, Furue M, Moroi Y. Expression and prognostic significance of Stat5a and E-cadherin in extramammary Paget\u2019s disease. J Cutan Pathol 34:33\u201338. https:\/\/doi.org\/10.1111\/j.1600-0560.2006.00568.x","DOI":"10.1111\/j.1600-0560.2006.00568.x"},{"key":"474_CR76","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1365-4632.2008.03643.x","volume":"47","author":"SY Chen","year":"2008","unstructured":"Chen SY, Takeuchi S, Moroi Y, Hayashida S, Kido M et al (2008) Concordant over-expression of transcription factor Sp1 and vascular endothelial growth factor in extramammary Paget\u2019s disease. Int J Dermatol 47:562\u2013566. https:\/\/doi.org\/10.1111\/j.1365-4632.2008.03643.x","journal-title":"Int J Dermatol"},{"key":"474_CR77","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.0303-6987.2004.00211.x","volume":"31","author":"T Kuivanen","year":"2004","unstructured":"Kuivanen T, Tanskanen M, Jahkola T, Impola U, Asko-Seljavaara S et al (2004) Matrilysin-1 (MMP-7) and MMP-19 are expressed by Paget\u2019s cells in extramammary Paget\u2019s disease. J Cutan Pathol 31:483\u2013491. https:\/\/doi.org\/10.1111\/j.0303-6987.2004.00211.x","journal-title":"J Cutan Pathol"},{"key":"474_CR78","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2340\/00015555-1453","volume":"92","author":"T Fujimura","year":"2012","unstructured":"Fujimura T, Kambayashi Y, Hidaka T, Hashimoto A, Haga T et al (2012) Comparison of Foxp3\u2009+\u2009regulatory T cells and CD163\u2009+\u2009macrophages in invasive and non-invasive extramammary Paget\u2019s disease. Acta Derm Venereol 92:625\u2013628. https:\/\/doi.org\/10.2340\/00015555-1453","journal-title":"Acta Derm Venereol"},{"key":"474_CR79","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ygyno.2018.09.026","volume":"151","author":"M van der Linden","year":"2018","unstructured":"van der Linden M, van Esch E, Bulten J, Dreef E, Massuger L et al (2018) The immune cell infiltrate in the microenvironment of vulvar Paget disease. Gynecol Oncol 151:453\u2013459. https:\/\/doi.org\/10.1016\/j.ygyno.2018.09.026","journal-title":"Gynecol Oncol"},{"key":"474_CR80","doi-asserted-by":"publisher","first-page":"e0211135","DOI":"10.1371\/journal.pone.0211135","volume":"14","author":"N Iga","year":"2019","unstructured":"Iga N, Otsuka A, Yamamoto Y, Nakashima C, Honda T et al (2019) Accumulation of exhausted CD8\u2009+\u2009T cells in extramammary Paget\u2019s disease. PLoS ONE 14:e0211135. https:\/\/doi.org\/10.1371\/journal.pone.0211135","journal-title":"PLoS ONE"},{"key":"474_CR81","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/cancers11060754","volume":"11","author":"SH Mauzo","year":"2019","unstructured":"Mauzo SH, Tetzlaff MT, Milton DR, Siroy AE, Nagarajan P et al (2019) Expression of PD-1 and PD-L1 in extramammary Paget disease: implications for immune-targeted therapy. Cancers 11:754. https:\/\/doi.org\/10.3390\/cancers11060754","journal-title":"Cancers"},{"key":"474_CR82","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/ajd.13607","volume":"62","author":"J Kato","year":"2021","unstructured":"Kato J, Sugita S, Horimoto K, Sato S, Yoneta D et al (2021) Expression of programmed cell death ligand 1 (PD-L1) at in situ and invasive extramammary Paget\u2019s disease and literature review. Australas J Dermatol 62:412\u2013414. https:\/\/doi.org\/10.1111\/ajd.13607","journal-title":"Australas J Dermatol"},{"key":"474_CR83","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12885-026-15829-2","volume":"26","author":"Y Nakamura","year":"2026","unstructured":"Nakamura Y, Yamazaki N, Namikawa K, Uchi H, Mori S et al (2026) Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1). BMC Cancer 26:467. https:\/\/doi.org\/10.1186\/s12885-026-15829-2","journal-title":"BMC Cancer"},{"key":"474_CR84","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/ijms23031813","volume":"23","author":"YR Woo","year":"2022","unstructured":"Woo YR, Cho SH, Lee JD, Kim HS (2022) The human microbiota and skin cancer. Int J Mol Sci 23:1813. https:\/\/doi.org\/10.3390\/ijms23031813","journal-title":"Int J Mol Sci"},{"key":"474_CR85","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1684\/ejd.2021.3972","volume":"31","author":"R Sakamoto","year":"2021","unstructured":"Sakamoto R, Kajihara I, Mijiddorj T, Otsuka-Maeda S, Sawamura S et al (2021) Existence of Staphylococcus aureus correlates with the progression of extramammary Paget\u2019s disease: potential involvement of interleukin-17 and M2-like macrophage polarization. Eur J Dermatol 31:48\u201354. https:\/\/doi.org\/10.1684\/ejd.2021.3972","journal-title":"Eur J Dermatol"},{"key":"474_CR86","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jaci.2018.11.015","volume":"143","author":"AS Paller","year":"2019","unstructured":"Paller AS, Kong HH, Seed P, Naik S, Scharschmidt TC et al (2019) The microbiome in patients with atopic dermatitis. J Allergy Clin Immunol 143:26\u201335. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.015","journal-title":"J Allergy Clin Immunol"},{"key":"474_CR87","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/cas.13005","volume":"107","author":"Y Kimura","year":"2016","unstructured":"Kimura Y, Nagai N, Tsunekawa N, Sato-Matsushita M, Yoshimoto T et al (2016) IL-17A-producing CD30(+) V\u03b41 T cells drive inflammation-induced cancer progression. Cancer Sci 107:1206\u20131214. https:\/\/doi.org\/10.1111\/cas.13005","journal-title":"Cancer Sci"},{"key":"474_CR88","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4143\/crt.2014.46.3.297","volume":"46","author":"Q Li","year":"2014","unstructured":"Li Q, Liu L, Zhang Q, Liu S, Ge D et al (2014) Interleukin-17 indirectly promotes M2 macrophage differentiation through stimulation of COX-2\/PGE2 pathway in the cancer cells. Cancer Res Treat 46:297\u2013306. https:\/\/doi.org\/10.4143\/crt.2014.46.3.297","journal-title":"Cancer Res Treat"},{"key":"474_CR89","first-page":"3062","volume":"8","author":"X Xu","year":"2015","unstructured":"Xu X, Shao N, Qiao D, Wang Z, Song N et al (2015) Expression of vascular endothelial growth factor and basic fibroblast growth factor in extramammary Paget disease. Int J Clin Exp Pathol 8:3062\u20133068 PMID: 26045818","journal-title":"Int J Clin Exp Pathol"},{"key":"474_CR90","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.2353\/ajpath.2009.090420","volume":"175","author":"S Hirakawa","year":"2009","unstructured":"Hirakawa S, Detmar M, Kerjaschki D, Nagamatsu S, Matsuo K et al (2009) Nodal lymphangiogenesis and metastasis: role of tumor-induced lymphatic vessel activation in extramammary Paget\u2019s disease. Am J Pathol 175:2235\u20132248. https:\/\/doi.org\/10.2353\/ajpath.2009.090420","journal-title":"Am J Pathol"},{"key":"474_CR91","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20:71\u201388. https:\/\/doi.org\/10.1038\/s41576-018-0071-5","journal-title":"Nat Rev Genet"},{"key":"474_CR92","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis M, Sledge GW, Jeffrey SS (2021) Liquid biopsy enters the clinic: implementation issues and future challenges. Nat Rev Clin Oncol 18:297\u2013312. https:\/\/doi.org\/10.1038\/s41571-020-00457-x","journal-title":"Nat Rev Clin Oncol"},{"key":"474_CR93","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1158\/2159-8290.CD-24-0206","volume":"14","author":"T Hashimoto","year":"2024","unstructured":"Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T et al (2024) The SCRUM-MONSTAR cancer-omics ecosystem: striving for a quantum leap in precision medicine. Cancer Discov 14:2243\u20132261. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0206","journal-title":"Cancer Discov"},{"key":"474_CR94","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ctrv.2011.04.002","volume":"38","author":"C Patriarca","year":"2012","unstructured":"Patriarca C, Macchi RM, Marschner AK, Mellstedt H (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 38:68\u201375. https:\/\/doi.org\/10.1016\/j.ctrv.2011.04.002","journal-title":"Cancer Treat Rev"},{"key":"474_CR95","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3892\/ijmm.2018.3764","volume":"42","author":"L Huang","year":"2018","unstructured":"Huang L, Yang Y, Yang F, Liu S, Zhu Z et al (2018) Functions of EpCAM in physiological processes and diseases (Review). Int J Mol Med 42:1771\u20131785. https:\/\/doi.org\/10.3892\/ijmm.2018.3764","journal-title":"Int J Mol Med"},{"key":"474_CR96","doi-asserted-by":"publisher","unstructured":"Yamada-Kanazawa S, Tasaki Y, Kajihara I, Sakamoto R, Maeda-Otsuka S et al. The expression of EpCAM in extramammary Paget\u2019s disease. Intractable Rare Dis Res 8:20\u201323. https:\/\/doi.org\/10.5582\/irdr.2019.01010","DOI":"10.5582\/irdr.2019.01010"},{"key":"474_CR97","first-page":"646","volume":"37","author":"SA Leon","year":"1977","unstructured":"Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646\u2013650 PMID: 837366","journal-title":"Cancer Res"},{"key":"474_CR98","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/bjd.17709","volume":"181","author":"T Mijiddorj","year":"2019","unstructured":"Mijiddorj T, Kajihara I, Tasaki Y, Otsuka-Maeda S, Sakamoto R et al (2019) Serum cell-free DNA levels are a useful marker for extramammary Paget disease. Br J Dermatol 181:505\u2013511. https:\/\/doi.org\/10.1111\/bjd.17709","journal-title":"Br J Dermatol"},{"key":"474_CR99","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/exd.14476","volume":"31","author":"S Sawamura","year":"2021","unstructured":"Sawamura S, Mijiddorj Myangat T, Kajihara I, Tanaka K et al (2021) Genomic landscape of circulating tumour DNA in metastatic extramammary Paget\u2019s disease. Exp Dermatol 31:341\u2013348. https:\/\/doi.org\/10.1111\/exd.14476","journal-title":"Exp Dermatol"}],"container-title":["Medical Molecular Morphology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00795-026-00474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00795-026-00474-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00795-026-00474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:29:02Z","timestamp":1789036142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00795-026-00474-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":99,"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1007\/s00795-026-00474-2","relation":{},"ISSN":["1860-1480","1860-1499"],"issn-type":[{"value":"1860-1480","type":"print"},{"value":"1860-1499","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}